Literature DB >> 35091888

Single nucleotide variants around the connective tissue growth factor (CTGF/CCN2) gene and their association with multiple sclerosis risk, disability scores, and rate of disease progression.

Birsen Can Demirdöğen1, Osman Oğuzhan Kılıç2, Elif Naz Karagülle2, Latife Mekselina Kalmaz2, Semra Mungan3.   

Abstract

BACKGROUND: This study aimed to explore the possible association of single nucleotide polymorphisms (SNPs) in the upstream (rs9402373) and downstream regions (rs9399005 and rs12526196) of the gene encoding connective tissue growth factor (CTGF/CCN2) with relapsing-remitting multiple sclerosis (RRMS) risk and clinical parameters including disability scores and rate of disability progression.
MATERIALS AND METHODS: In total, 200 patients with RRMS and 305 controls were genotyped using real-time PCR (rs1252696 C/T and rs9402373 G/C) or PCR-RFLP (rs9399005 C/T) methods. Furthermore, the association between these genotypes and clinical parameters including Expanded Disability Status Scale (EDSS) score, Multiple Sclerosis Severity Score (MSSS), age at onset, duration of disease, duration of treatment, and presence of contrast-enhancing lesions was analyzed.
RESULTS: rs9399005 genotypes TT and CT in the dominant model were significant predictors of RRMS vs. control status by logistic regression analysis (OR = 1.45, 95% CI = 1.01-2.08, P = .04). Moreover, these genotypes for rs9399005 were associated with a MSSS ≥ 2.4 (OR = 3.54, 95% CI = 1.56-8.05, P = .003). In addition, MSSS was lower in patients who had at least one rs12526196C allele than in the corresponding patients with the TT genotype (P = .02).
CONCLUSION: To our knowledge, this is the first evidence of the involvement of variants around the CTGF gene in MS risk and disability progression.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  EDSS; MSSS; Neurodegeneration; Oligodendrocyte; Prognosis; Progression

Mesh:

Substances:

Year:  2022        PMID: 35091888     DOI: 10.1007/s10072-021-05852-5

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  25 in total

1.  Expression of connective tissue growth factor in human renal fibrosis.

Authors:  Y Ito; J Aten; R J Bende; B S Oemar; T J Rabelink; J J Weening; R Goldschmeding
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

2.  Expression of connective tissue growth factor in experimental rat and human liver fibrosis.

Authors:  V Paradis; D Dargere; M Vidaud; A C De Gouville; S Huet; V Martinez; J M Gauthier; N Ba; R Sobesky; V Ratziu; P Bedossa
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

3.  Oligodendrocyte progenitor cell susceptibility to injury in multiple sclerosis.

Authors:  Qiao-Ling Cui; Tanja Kuhlmann; Veronique E Miron; Soo Yuen Leong; Jun Fang; Pavel Gris; Timothy E Kennedy; Guillermina Almazan; Jack Antel
Journal:  Am J Pathol       Date:  2013-06-05       Impact factor: 4.307

4.  Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis.

Authors:  J A Lasky; L A Ortiz; B Tonthat; G W Hoyle; M Corti; G Athas; G Lungarella; A Brody; M Friedman
Journal:  Am J Physiol       Date:  1998-08

5.  Paracrine control of oligodendrocyte differentiation by SRF-directed neuronal gene expression.

Authors:  Christine Stritt; Sina Stern; Kai Harting; Thomas Manke; Daniela Sinske; Heinz Schwarz; Martin Vingron; Alfred Nordheim; Bernd Knöll
Journal:  Nat Neurosci       Date:  2009-03-08       Impact factor: 24.884

Review 6.  CTGF/CCN2 from Skeletal Muscle to Nervous System: Impact on Neurodegenerative Diseases.

Authors:  David Gonzalez; Enrique Brandan
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

7.  Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis.

Authors:  A Igarashi; K Nashiro; K Kikuchi; S Sato; H Ihn; G R Grotendorst; K Takehara
Journal:  J Invest Dermatol       Date:  1995-08       Impact factor: 8.551

8.  Multiple sclerosis: pathogenesis and treatment.

Authors:  Ingrid Loma; Rock Heyman
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363

9.  Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex.

Authors:  Ebru Ercan; Juliette M Han; Alessia Di Nardo; Kellen Winden; Min-Joon Han; Leonie Hoyo; Afshin Saffari; Andrew Leask; Daniel H Geschwind; Mustafa Sahin
Journal:  J Exp Med       Date:  2017-02-09       Impact factor: 14.307

10.  Multiple sclerosis: Pathology, diagnosis and treatments.

Authors:  Wen-Juan Huang; Wei-Wei Chen; Xia Zhang
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.